Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome: A randomized controlled study in 274 patients by F. Lainé et al.
Metabolic and hepatic effects of bloodletting in
dysmetabolic iron overload syndrome: A randomized
controlled study in 274 patients
Submitted by Véronique Bourgeais on Tue, 02/12/2019 - 15:37
Titre Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome:A randomized controlled study in 274 patients
Type de
publication Article de revue
Auteur
Lainé, Fabrice [1], Ruivard, Marc [2], Loustaud-Ratti, Véronique [3], Bonnet, Fabrice
[4], Calès, Paul [5], Bardou-Jacquet, Edouard [6], Sacher-Huvelin, Sylvie [7], Causse,
Xavier [8], Beusnel, Christine [9], Renault, Alain [10], Bellissant, Eric [11], Deugnier,
Yves [12]
Organisme Study Group [13]
Editeur Wiley











Adult [14], Aged [15], Analysis of Variance [16], Blood Chemical Analysis [17], Chi-
Square Distribution [18], Female [19], Ferritins [20], Follow-Up Studies [21], Humans
[22], Insulin resistance [23], Iron Overload [24], Life Style [25], Liver Function Tests
[26], Magnetic Resonance Imaging [27], Male [28], Middle Aged [29], Phlebotomy
[30], Prospective Studies [31], Reference Values [32], Risk Assessment [33], Severity
of Illness Index [34], Treatment Outcome [35], Weight Gain [36]
Résumé en
anglais
Dysmetabolic iron overload syndrome (DIOS) is a common cause of hyperferritinemia,
accounting for a mild increase of iron stores in insulin-resistant subjects. Iron removal
could improve insulin sensitivity. We performed a prospective, randomized, controlled
trial (NCT01015525) in nondiabetic DIOS patients with hepatic iron >50 μmol/g at
magnetic resonance imaging to compare the metabolic and hepatic outcomes of 1-year
maintenance of serum ferritin levels <50 μg/L by bloodletting associated with lifestyle
and diet advice (LFDA) to those of LFDA only. Patients were randomly assigned (1:1)
with stratification by center (n = 8) and hyperglycemia (>5.6 mmol/L). Sample size
was calculated to provide 90% power and a difference in fasting glycemia of 0.25
mmol/L. Analysis was done in an intention-to-treat population. In 2010-2014, 146
patients were randomly assigned to receive venesections with LFDA and 128 to LFDA
only. At the end of the study, comparison of iron-depleted patients and controls
showed ferritin levels 71 ± 48 μg/L after removal of 4.9 ± 1.6 L of blood versus 733 ±
277 μg/L (P < 0.0001), glycemia 5.44 ± 0.7 versus 5.49 ± 0.7 mmol/L (P = 0.57), body
weight +0.5 ± 4.3% versus -0.6 ± 3.3% (P = 0.03), homeostasis model of assessment
of insulin resistance 3.39 versus 2.40 (P = 0.002), alanine aminotransaminase 33 ± 22
versus 37 ± 21 IU/L (P = 0.10), aspartate aminotransaminase 27 ± 13 versus 27 ± 10
IU/L (P = 0.81), gamma-glutamyl transferase 54 ± 138 versus 49 ± 35 IU/L (P = 0.72),
Fatty Liver Index 58.9 ± 24.6 versus 61.2 ± 22.9 (P = 0.37), and Fibrosis-4 score 1.5
± 0.6 versus 1.30 ± 0.6 (P = 0.51). Fatigue occurred in 25.3% of venesected patients
versus 2.3% of controls (P < 0.0001). In the subgroup of patients who lost weight,
glycemia, homeostasis model of assessment of insulin resistance, serum ferritin, lipid
profile, and liver function tests improved irrespective of bloodletting.
CONCLUSION: In DIOS patients, iron depletion by bloodletting does not improve
metabolic and hepatic features, is associated with weight gain, and is not as well
tolerated as expected; sustained modification of diet and lifestyle habits remains the
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